Alexander's (ALX) Q4 FFO and Revenues Surpass Estimates
Alexander's (ALX) came out with quarterly funds from operations (FFO) of $4.06 per share, beating the Zacks Consensus Estimate of $3.71 per share. This compares to FFO of $4.99 per share a year ago.
Alexander's: Bloomberg Lease Secured, Is The Dividend Safe
Alexander's has dipped materially from its 52-week high following a spike in the US 10-year Treasury yield. The REIT generated fiscal 2024 third-quarter FFO of $2.84 per share, down from its year-ago comp. A $354.8 million cash and cash equivalents position helps to provide a buffer for the REIT, but 2025 debt maturities are heavy and will pose a challenge.
Alexander's Is A Good Business That The Market Has Overestimated
Alexander's, Inc. has underperformed since 2019, with a -1.7% TSR compared to SPY's 113%, due to declining profitability and rich valuations. Despite increasing NOPAT since 2020, the Company's GAAP net income and NOPAT margins have declined from 2019 highs, impacting overall profitability. Management has created value with $154 million in economic earnings since 2019, but ALX remains overvalued with unrealistic growth expectations.
Alexander's (ALX) Tops Q3 FFO and Revenue Estimates
Alexander's (ALX) came out with quarterly funds from operations (FFO) of $2.84 per share, beating the Zacks Consensus Estimate of $2.57 per share. This compares to FFO of $3.63 per share a year ago.
Best Income Stocks to Buy for September 18th
ALX, JSAIY and NBTB made it to the Zacks Rank #1 (Strong Buy) income stocks list on September 18, 2024.
New Strong Buy Stocks for September 18th
SN, ALX, BPOP, ARCAY and JSAIY have been added to the Zacks Rank #1 (Strong Buy) List on September 18, 2024.
Best Income Stocks to Buy for September 13th
BANF, ALX and BPRN made it to the Zacks Rank #1 (Strong Buy) income stocks list on September 13, 2024.
ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations
ALX Oncology's Evorpacept, a first-in-class CD47 inhibitor, shows promising results in cancer treatment with reduced side effects and a favorable safety profile. Evorpacept's combination with TRP demonstrated improved response rates and longer duration of response in HER2-positive gastric and GEJ cancer trials. The ASPEN-06 trial also showed favorable results, with a 40.3% ORR in HER2-positive gastric/GEJ cancer, higher than the control group's 26.6%.
3 Highly Ranked REITs to Buy with Rate Cuts Ahead
With the possibility of multiple rate cuts back on the table this year, Real Estate Investment Trusts (REITs) may stand to benefit the most as these equities rely on debt to finance their operations and acquire properties.
Alexander's (ALX) Upgraded to Strong Buy: Here's What You Should Know
Alexander's (ALX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Best Income Stocks to Buy for August 9th
NREF, DKL and ALX made it to the Zacks Rank #1 (Strong Buy) income stocks list on August 9, 2024.
Alexander's (ALX) Beats Q2 FFO and Revenue Estimates
Alexander's (ALX) came out with quarterly funds from operations (FFO) of $3.31 per share, beating the Zacks Consensus Estimate of $2.57 per share. This compares to FFO of $3.55 per share a year ago.
